Price
Financials
Consolidated, Rs crore| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 35 | 34 | 41 | 39 | 29 | 25 | 37 | 26 | 21 | 21 | 16 | 12 |
| Expenses | 36 | 40 | 40 | 67 | 40 | 25 | 35 | 28 | 22 | 22 | 27 | 152 |
| Operating Profit | -0 | -6 | 1 | -28 | -11 | -1 | 1 | -2 | -0 | -1 | -11 | -140 |
| OPM % | -0.9% | -18% | 3.1% | -74% | -37% | -2.6% | 2.9% | -10% | -1.3% | -4.6% | -68% | -1,169% |
| Other Income | 0 | 2 | 0 | 8 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 6 |
| Interest | 11 | 12 | 13 | -33 | 0 | 0 | 0 | 2 | 1 | 2 | 1 | 1 |
| Depreciation | 5 | 5 | 5 | 6 | 4 | 4 | 7 | 6 | 5 | 5 | 5 | 12 |
| Profit before tax | -16 | -20 | -17 | 7 | -15 | -5 | -6 | -5 | -5 | -7 | -17 | -147 |
| Tax % | 0% | 0% | -3% | 21% | 0% | 0% | 0% | 2% | 0% | 0% | 0% | 0% |
| Net Profit | -16 | -20 | -16 | 5 | -15 | -5 | -6 | -6 | -5 | -7 | -17 | -147 |
| EPS in Rs | -1.88 | -2.45 | -1.94 | 0.63 | -1.84 | -0.62 | -0.72 | -0.68 | -0.66 | -0.88 | -2.00 | -17.74 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,380 | 1,346 | 1,462 | 1,186 | 1,315 | 1,059 | 861 | 237 | 187 | 149 | 116 | 70 |
| Expenses | 1,156 | 1,111 | 1,057 | 971 | 1,135 | 1,049 | 830 | 245 | 374 | 182 | 129 | 222 |
| Operating Profit | 224 | 234 | 404 | 215 | 180 | 10 | 32 | -8 | -187 | -33 | -13 | -152 |
| OPM % | 16% | 17% | 28% | 18% | 14% | 1.0% | 3.7% | -3.3% | -100% | -22% | -11% | -218% |
| Other Income | 6 | 11 | 8 | 10 | 23 | 8 | 10 | 1 | 1 | 10 | 4 | 6 |
| Interest | 86 | 84 | 68 | 82 | 70 | 61 | 56 | 40 | 36 | 3 | 3 | 4 |
| Depreciation | 66 | 61 | 58 | 56 | 67 | 67 | 56 | 18 | 108 | 20 | 20 | 26 |
| Profit before tax | 78 | 100 | 286 | 86 | 66 | -109 | -70 | -65 | -331 | -46 | -32 | -176 |
| Tax % | 7% | 16% | 25% | 11% | 13% | -0% | 3% | 4% | -1% | -1% | 0% | 0% |
| Net Profit | 72 | 84 | 214 | 76 | 57 | -109 | -72 | -68 | -329 | -45 | -32 | -176 |
| EPS in Rs | 8.90 | 10.33 | 26.41 | 9.44 | 6.95 | -13.16 | -8.67 | -8.16 | -39.62 | -5.48 | -3.85 | -21.28 |
| Dividend Payout % | 0% | 0% | 2% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | -26% | -39% | -28% | -40% | ||
| Compounded Profit Growth | % | % | 14% | -452% | ||
| Stock Price CAGR | -26% | -23% | 5% | % | ||
| Return on Equity | % | % | % | % |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 479 | 505 | 718 | 885 | 602 | 493 | 415 | 348 | 23 | -22 | -52 | -227 |
| Borrowings | 1,076 | 1,015 | 1,011 | 1,149 | 1,280 | 1,268 | 326 | 359 | 379 | 377 | 376 | 397 |
| Other Liabilities | 327 | 519 | 317 | 343 | 431 | 432 | 532 | 543 | 658 | 579 | 580 | 567 |
| Total Liabilities | 1,898 | 2,055 | 2,062 | 2,394 | 2,329 | 2,210 | 1,289 | 1,266 | 1,076 | 950 | 921 | 753 |
| Fixed Assets | 813 | 814 | 879 | 1,035 | 965 | 1,045 | 502 | 520 | 436 | 418 | 408 | 386 |
| CWIP | 90 | 94 | 76 | 65 | 122 | 89 | 60 | 40 | 21 | 21 | 17 | 18 |
| Investments | 3 | 3 | 3 | 3 | 3 | 86 | 199 | 199 | 199 | 168 | 168 | 181 |
| Other Assets | 992 | 1,144 | 1,104 | 1,290 | 1,239 | 990 | 529 | 507 | 421 | 343 | 328 | 170 |
| Total Assets | 1,898 | 2,055 | 2,062 | 2,394 | 2,329 | 2,210 | 1,289 | 1,266 | 1,076 | 950 | 921 | 753 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 140 | 154 | 58 | 21 | 422 | 80 | 567 | 28 | 35 | -24 | -2 | 8 |
| Cash from Investing Activity | -107 | -190 | -68 | -164 | -89 | -196 | 404 | -16 | -5 | 28 | -5 | -1 |
| Cash from Financing Activity | -42 | 41 | 35 | 186 | -338 | 72 | -1,015 | -10 | -34 | -6 | 5 | -6 |
| Net Cash Flow | -8 | 4 | 25 | 44 | -5 | -44 | -44 | 1 | -3 | -2 | -1 | 1 |
| Free Cash Flow | 16 | 95 | -11 | -142 | 333 | -33 | 1,084 | 11 | 30 | -26 | -6 | 7 |
| CFO/OP | 63% | 66% | 23% | 30% | 243% | 972% | 1,720% | -352% | -19% | 73% | 13% | -5% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 87 | 88 | 50 | 85 | 99 | 86 | 46 | 134 | 145 | 203 | 233 | 236 |
| Inventory Days | 244 | 294 | 329 | 411 | 397 | 396 | 263 | 573 | 216 | 327 | 358 | 63 |
| Days Payable | 107 | 98 | 122 | 154 | 207 | 179 | 35 | 100 | 74 | 225 | 240 | 263 |
| Cash Conversion Cycle | 224 | 285 | 258 | 342 | 288 | 303 | 274 | 607 | 286 | 305 | 351 | 36 |
| Working Capital Days | 43 | 58 | 55 | 121 | 68 | 216 | 77 | 195 | -15 | -171 | -255 | -1,468 |
| ROCE % | 11% | 12% | 22% | 9% | 7% | -3% | -1% | -3% | -52% | -11% | -8% | -65% |
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 20.94% | 20.94% | 20.94% | 20.94% | 20.94% | 20.94% | 20.94% | 20.94% | 7.76% | 7.76% | 7.76% | 7.57% |
| FIIs | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% |
| Government | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% |
| Public | 77.30% | 77.29% | 77.30% | 77.29% | 77.30% | 77.30% | 77.30% | 77.30% | 90.47% | 90.47% | 90.47% | 90.66% |
| No. of Shareholders | 49,503 | 49,038 | 49,027 | 49,016 | 49,012 | 49,003 | 49,005 | 48,957 | 48,928 | 48,925 | 49,221 | 47,492 |
Fundamentals
Market Cap₹ 44.9 Cr.
Current Price₹ 5.41
Book Value₹ -25.4
ROCE-65.2 %
ROE%
Dividend Yield0.00 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)-40%
Compounded Profit Growth (TTM)-452%
Consolidated figures.
Valuation
Market capRs 47 Cr
Enterprise valueRs 443 Cr
Price to book-0.22x
Price to sales0.68x
EV / sales6.33x
Price to cash flow6.15x
Earnings yield-372.69%
P/B, 3-year average-4.34x
P/B, 5-year average-1.74x
Profitability
Operating margin (excl. other income)-217.79%
Operating margin (incl. other income)-208.76%
EBITDA margin-208.74%
Pre-tax margin-251.95%
Net profit margin-252.12%
Net margin, latest quarter-1226.00%
ROE143.63%
ROCE-65.22%
ROA-21.08%
ROE, 3-year average11.09%
ROCE, 3-year average-28.06%
ROA, 3-year average-9.66%
ROE, 5-year average-29.30%
ROCE, 5-year average-27.83%
ROA, 5-year average-12.47%
ROIC (approx.)-92.93%
Tax rate-0.08%
Other income / net worth-3.00%
Growth
Sales growth (latest year)-39.80%
Sales CAGR, 3 years-27.95%
Sales CAGR, 5 years-39.47%
Sales growth QoQ-24.95%
Sales growth YoY (latest quarter)-53.14%
Per share
EPS (TTM)Rs -21.28
EPS (latest quarter)Rs -17.74
EPS, 3-year averageRs -4.67
EPS, 5-year averageRs -14.28
Book value per shareRs -25.39
Sales per shareRs 8.44
Cash flow per shareRs 0.93
Free cash flow per shareRs 0.84
Efficiency
Asset turnover0.09x
Fixed asset turnover0.18x
Inventory turnover5.80x
Inventory days63 days
Debtor days236 days
Debtors turnover1.54x
Creditor days263 days
Cash conversion cycle36 days
Working capital days-1468 days
Leverage
Total debtRs 397 Cr
Cash and bankRs 1 Cr
Net debtRs 396 Cr
Debt to equity-1.89x
Interest coverage-41.09x
Owners' fund to total sources-27.95%
Debt to assets52.73%
Cash flow
Cash from Operating Activity (latest year)Rs 8 Cr
Cash from Investing Activity (latest year)Rs -1 Cr
Cash from Financing Activity (latest year)Rs -6 Cr
Net Cash Flow (latest year)Rs 1 Cr
Free cash flow (latest year)Rs 7 Cr
FCFE (approx.: FCF + change in debt)Rs 28 Cr
Sales to cash flow9.09x
Statement figures
Net sales (TTM)Rs 70 Cr
Net sales (latest year)Rs 70 Cr
Sales (latest quarter)Rs 12 Cr
Operating profit excl. other income (latest year)Rs -152 Cr
Operating profit (latest quarter)Rs -140 Cr
Other income (TTM)Rs 6 Cr
EBITDA (TTM)Rs -146 Cr
PBDT (TTM)Rs -150 Cr
Profit before tax (TTM)Rs -176 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs -176 Cr
Net profit (latest year)Rs -176 Cr
Net profit (latest quarter)Rs -147 Cr
Depreciation (TTM)Rs 26 Cr
Depreciation (latest quarter)Rs 12 Cr
Interest (TTM)Rs 4 Cr
Cost of goods sold (latest year)Rs 74 Cr
Total expenditure (latest year)Rs 222 Cr
Total income (latest year)Rs 76 Cr
Share capitalRs 17 Cr
ReservesRs -227 Cr
Shareholders' fundsRs -211 Cr
Total assetsRs 753 Cr
Net blockRs 386 Cr
Capital work in progressRs 18 Cr
InvestmentsRs 181 Cr
ReceivablesRs 45 Cr
InventoryRs 13 Cr
Other liabilitiesRs 567 Cr
Shares outstanding (crore)8.29
Ownership
Promoter holding7.57% (-13.37 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | VIVIMEDLAB | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +4.8% | -2.8% | +7.6 pts |
| 1 month | -16.0% | -6.8% | -9.2 pts |
| 3 months | -1.4% | -7.6% | +6.2 pts |
| 6 months | +8.1% | +0.4% | +7.7 pts |
| 1 year | -51.6% | -9.9% | -41.7 pts |
| 2 years | -68.6% | -13.6% | -55.1 pts |
| 3 years | +15.4% | +14.2% | +1.2 pts |
| 5 years | -71.8% | +27.9% | -99.7 pts |
Red flags
F-score 3 of 8| serious | Negative equity Shareholders' equity is negative |
| look | Repeated losses Net loss in each of the last two years |
| look | On NSE surveillance On NSE surveillance: Insolvency |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2026Sales ₹12 Cr -53.8% vs Mar 2025.
Net loss ₹147 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2024-12-27 | Annual General Meeting | |
| 2023-11-07 | Annual General Meeting | |
| 2023-03-21 | Annual General Meeting | |
| 2023-02-10 | Annual General Meeting | |
| 2020-12-23 | Annual General Meeting | |
| 2019-09-23 | Annual General Meeting | |
| 2018-09-19 | Annual General Meeting/Dividend Re 0.40 Per Share | |
| 2017-09-21 | Annual General Meeting/Dividend - Re 0.40 Per Share | |
| 2016-09-22 | Annual General Meeting | |
| 2016-04-06 | Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share | 0.2000 |
| 2015-09-23 | Annual General Meeting | |
| 2014-09-24 | Annual General Meeting / Dividend - Rs 3/- Per Share | |
| 2013-09-24 | Annual General Meeting / Dividend - Rs 3/- Per Share | |
| 2012-09-21 | Annual General Meeting/Dividend Rs 3 Per Share | |
| 2011-09-26 | Annual General Meeting And Dividend - Rs.2 Per Share | |
| 2010-09-09 | Annual General Meeting And Dividend Rs.1.50 Per Share | |
| 2009-09-24 | Agm/Div-Rs.1.50 Per Share | |
| 2008-09-22 | Agm/Dividend - 10% | |
| 2007-12-20 | Annual General Meeting | |
| 2006-09-21 | Agm |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
EPS in the scrip is zero (4 trailing quarters)Insolvency Resolution Process(IRP)Less than 100 unique PAN traded in previous 30 days
Quick answers
What is the market cap of Vivimed Labs Ltd?
Vivimed Labs Ltd (VIVIMEDLAB) has a market capitalisation of Rs 44.9 Cr. at the 2026-10-01 close.
What were Vivimed Labs Ltd's latest quarterly results?
In the Mar 2026 quarter, Vivimed Labs Ltd sales was Rs 12 Cr (-53.8% vs Mar 2025) with a net loss of Rs 147 Cr.
What is the 52-week high and low of Vivimed Labs Ltd?
The 52-week high is Rs 29.40 and the 52-week low is Rs 4.75.